| III.1 |
Cellular and Gene Therapy for Cardiac Disease: FDA Product and Pre-Clinical Regulatory Considerations |
|
Wei Liang PhD and Brent McCright PhD |
| III.2 |
Cellular Therapy Product Development for Cardiac Repair and cGMP Manufacturing |
|
Todd R Flower PhD |
| III.3 |
Autologous Myocardial Repair and Regeneration through Intracoronary Administration of Allogeneic Cardiac Stem Cells and/or Growth Factors |
|
Bernardo Nadal-Ginard MD PhD, Georgina M Ellison PhD
and Daniele Torella MD PhD |
| III.4 |
Tissue Engineering and Applications for Treatment of Myocardial Infarction |
|
Aboli A Rane PhD, John Watson PhD and Karen L Christman PhD |
| III.5 |
Mouse, Rat, Sheep and Pig as Functional Models for Cell Therapy |
|
Jonathan Dinsmore PhD |
| III.6 |
Pathology Assessment for Regenerative Therapy |
|
Stefanie Dimmeler PhD, Annarosa Leri MD, Marcello Rota PhD,
Marion Muhly-Reinholz MTA, Andreas M Zeiher MD
and Piero Anversa MD |
| III.7 |
Cellular and Molecular Imaging in Translational Cardiovascular Research |
|
Johannes Riegler PhD and Joseph C Wu MD PhD |
| III.8 |
Methods of Stem Cell Delivery |
|
Nabil Dib MD MSc |
| III.9 |
Clinical Trial Design and Endpoints for Cardiovascular Stem Cell Therapies |
|
Marko Banovic MD PhD, Atta Behfar MD PhD,
Marc Vanderheyden MD PhD, Branko Beleslin MD PhD,
Andreas M Zeiher MD, Andre Terzic MD PhD
and Jozef Bartunek MD PhD |
